TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 29083050

Group type: EXPERIMENTAL
Intervention: R-CHOP
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: R-cytarabine
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: R-CHOP and R-cytarabine alternating regimen
Number of subjects: 73
Study: 29084559

Group type: EXPERIMENTAL
Intervention: Prepex circumcision
Number of subjects: 304
Study: 29084708

Group type: EXPERIMENTAL
Intervention: Power Up mobile phone app
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Interviews and focus groups with 30 young people, parents, and clinicians
Number of subjects: 60
Study: 29084797

Group type: EXPERIMENTAL
Intervention: PSA testing in UK GP
Number of subjects: 1000

Group type: COMPARATOR
Intervention: PSA level ≥3 in UK GP
Number of subjects: 1000
Study: 29084869

Group type: EXPERIMENTAL
Intervention: Early intravenous immunoglobulin treatment
Number of subjects: 0
Study: 29085669

Group type: EXPERIMENTAL
Intervention: Aliskiren
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (HCTZ)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 29085815

Group type: EXPERIMENTAL
Intervention: Resident training programs (talks, day camps, thematic activities) in the intervention group.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group with no program implemented.
Number of subjects: 0
Study: 29086340

Group type: EXPERIMENTAL
Intervention: Herpes zoster patients without post-herpetic neuralgia (PHN)
Number of subjects: 412

Group type: EXPERIMENTAL
Intervention: Herpes zoster patients with post-herpetic neuralgia (PHN)
Number of subjects: 412
Study: 29086392

Group type: EXPERIMENTAL
Intervention: Combination of hydralazine and isosorbide dinitrate (Hy+ISDN)
Number of subjects: 0
Study: 29086499

Group type: EXPERIMENTAL
Intervention: Increased physical activity (PA) by 160% ± 23%
Number of subjects: 14

Group type: COMPARATOR
Intervention: Increased physical activity (PA) by 34% ± 25%
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Energy intake (EI) changes of -8.7% ± 5.6%
Number of subjects: 14

Group type: COMPARATOR
Intervention: Energy intake (EI) changes of -7.4% ± 2.7%
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Changes in PA
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Changes in EI
Number of subjects: 14
Study: 29086504

Group type: EXPERIMENTAL
Intervention: WL + AT
Number of subjects: 249

Group type: EXPERIMENTAL
Intervention: WL + RT
Number of subjects: 249

Group type: COMPARATOR
Intervention: WL
Number of subjects: 249
Study: 29086529

Group type: EXPERIMENTAL
Intervention: Weight loss attempts
Number of subjects: 3008

Group type: EXPERIMENTAL
Intervention: Perception of obesity as a disease
Number of subjects: 3008

Group type: EXPERIMENTAL
Intervention: Concern about weight affecting future health
Number of subjects: 3008

Group type: EXPERIMENTAL
Intervention: Responsibility for weight loss
Number of subjects: 3008

Group type: EXPERIMENTAL
Intervention: Self-identification as obese
Number of subjects: 3008

Group type: EXPERIMENTAL
Intervention: Scheduled follow-up for weight-related conversations
Number of subjects: 3008

Group type: EXPERIMENTAL
Intervention: Perception of employer-sponsored wellness offerings
Number of subjects: 3008
Study: 29086923

Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A (BoNT/A)
Number of subjects: 0
Study: 29087448

Group type: EXPERIMENTAL
Intervention: Preadmission functional decline
Number of subjects: 2011

Group type: EXPERIMENTAL
Intervention: Severe cognitive impairment
Number of subjects: 2011

Group type: EXPERIMENTAL
Intervention: Visual impairment
Number of subjects: 2011

Group type: EXPERIMENTAL
Intervention: Weight loss
Number of subjects: 2011

Group type: EXPERIMENTAL
Intervention: Hearing impairment
Number of subjects: 2011

Group type: EXPERIMENTAL
Intervention: Mild cognitive impairment
Number of subjects: 2011
Study: 29087741

Group type: EXPERIMENTAL
Intervention: Long-term supplemental oxygen treatment
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control (no long-term supplemental oxygen)
Number of subjects: 34
Study: 29089191

Group type: EXPERIMENTAL
Intervention: Quadrivalent live attenuated influenza vaccine (LAIV4) or inactivated influenza vaccine (IIV4)
Number of subjects: 266

Group type: EXPERIMENTAL
Intervention: Text messaging for reporting symptoms
Number of subjects: 266

Group type: COMPARATOR
Intervention: Text messaging versus paper reporting
Number of subjects: 266
Study: 29089314

Group type: EXPERIMENTAL
Intervention: everolimus-eluting Absorb BVS (n=2164)
Number of subjects: 3389

Group type: COMPARATOR
Intervention: cobalt-chromium everolimus-eluting stents (n=1225)
Number of subjects: 3389
Study: 29089744

Group type: EXPERIMENTAL
Intervention: Rohto Dry-Aid
Number of subjects: 0

Group type: COMPARATOR
Intervention: Systane Ultra
Number of subjects: 0
Study: 29090343

Group type: EXPERIMENTAL
Intervention: Intensive treatment
Number of subjects: 3525

Group type: COMPARATOR
Intervention: Non-intensive treatment or best supportive care
Number of subjects: 3525

Group type: EXPERIMENTAL
Intervention: Age-specific AML incidence rates
Number of subjects: 3525

Group type: EXPERIMENTAL
Intervention: ELN risk categorization
Number of subjects: 3525

Group type: EXPERIMENTAL
Intervention: ECOG performance status < 2
Number of subjects: 3525

Group type: EXPERIMENTAL
Intervention: HCT-CI comorbidity index < 3
Number of subjects: 3525

Group type: EXPERIMENTAL
Intervention: Activating FLT3 mutations
Number of subjects: 3525
Study: 29090520

Group type: EXPERIMENTAL
Intervention: Hispanic patients
Number of subjects: 730

Group type: COMPARATOR
Intervention: Non-Hispanic patients
Number of subjects: 730
Study: 29091557

Group type: EXPERIMENTAL
Intervention: Single intravenous infusion of adeno-associated virus serotype 9 carrying SMN complementary DNA
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: High-dose cohort of adeno-associated virus serotype 9
Number of subjects: 15
Study: 29092017

Group type: EXPERIMENTAL
Intervention: Surgical correction of pectus carinatum (PC)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Conservative compression treatment
Number of subjects: 6
Study: 29092051

Group type: EXPERIMENTAL
Intervention: Sustained obesity (cumulative excess BMI ≥5 kg/m2) in men age >35 years and women age <35 years
Number of subjects: 665

Group type: EXPERIMENTAL
Intervention: Age >35 years
Number of subjects: 665

Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 665

Group type: EXPERIMENTAL
Intervention: Cumulative excess BMI (ceBMI) values ≥0 kg/m2 and ≥5 kg/m2
Number of subjects: 665

Group type: EXPERIMENTAL
Intervention: Overall cohort
Number of subjects: 665
Study: 29092792

Group type: EXPERIMENTAL
Intervention: Patients with severe postoperative complications
Number of subjects: 137

Group type: COMPARATOR
Intervention: Patients without severe postoperative complications
Number of subjects: 137
Study: 29092845

Group type: EXPERIMENTAL
Intervention: Statin therapy
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Chronic kidney disease
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Acute coronary syndrome
Number of subjects: 84
Study: 29092878

Group type: EXPERIMENTAL
Intervention: Isolated soluble fiber supplementation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 29092957

Group type: EXPERIMENTAL
Intervention: Genomic and transcriptomic profiling of liver metastases from PNET patients.
Number of subjects: 5
Study: 29093707

Group type: EXPERIMENTAL
Intervention: Add-on Pyridostigmine (PDG)
Number of subjects: 7
Study: 29093819

Group type: EXPERIMENTAL
Intervention: Dialectical Behaviour Therapy (DBT) adapted for Adolescents
Number of subjects: 39

Group type: COMPARATOR
Intervention: Enhanced usual care
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Full-syndrome BPD
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Sub-threshold BPD
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: All participants (DBT and enhanced usual care)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Adolescents with BPD
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: High baseline level of clinician-rated depressive symptoms
Number of subjects: 39
Study: 29094043

Group type: EXPERIMENTAL
Intervention: Robot-assisted passive hand mobilization for 20 minutes
Number of subjects: 23
Study: 29094152

Group type: EXPERIMENTAL
Intervention: Kansas City Cardiomyopathy Questionnaire Overall Summary scores (KCCQ-os)
Number of subjects: 3041

Group type: EXPERIMENTAL
Intervention: Current KCCQ-os scores
Number of subjects: 3041

Group type: EXPERIMENTAL
Intervention: Change in KCCQ-os scores
Number of subjects: 3041

Group type: EXPERIMENTAL
Intervention: All-cause death
Number of subjects: 3041
Study: 29095433

Group type: EXPERIMENTAL
Intervention: Mild neonatal encephalopathy (NE) infants
Number of subjects: 63

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 63
Study: 29095677

Group type: EXPERIMENTAL
Intervention: R-CHOP (rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone)
Number of subjects: 504

Group type: EXPERIMENTAL
Intervention: R-FM (rituximab plus fludarabine and mitoxantrone)
Number of subjects: 504

Group type: COMPARATOR
Intervention: R-CVP (rituximab plus cyclophosphamide, vincristine, and prednisone)
Number of subjects: 504
Study: 29095678

Group type: EXPERIMENTAL
Intervention: Pembrolizumab 10 mg/kg every 2 weeks for up to 24 months
Number of subjects: 24
Study: 29095970

Group type: EXPERIMENTAL
Intervention: Step reduction (SR; <1,000 steps.d-1 for 14 d)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Recovery (RC) after step reduction
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Step reduction (SR)
Number of subjects: 22
Study: 29095983

Group type: EXPERIMENTAL
Intervention: Metformin (1 g twice daily) for 9.4 to 13.7 weeks
Number of subjects: 10
Study: 29096229

Group type: EXPERIMENTAL
Intervention: L3 skeletal muscle index (L3SMI)
Number of subjects: 231
Study: 29096647

Group type: EXPERIMENTAL
Intervention: HCV knowledge assessment for patients
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: HCV knowledge assessment for staff
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Access to HCV medical treatment for HCV-positive patients
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Barriers to HCV-related services
Number of subjects: 240
Study: 29096668

Group type: EXPERIMENTAL
Intervention: Lenalidomide monotherapy
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Lenalidomide plus rituximab
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Lenalidomide plus other treatment
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Overall response rate to lenalidomide-based therapy
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Treatment-emergent adverse events after lenalidomide-containing therapy
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Median duration of response
Number of subjects: 58
Study: 29096670

Group type: EXPERIMENTAL
Intervention: E/C/F/TDF plus darunavir 800 mg daily
Number of subjects: 10
Study: 29096697

Group type: EXPERIMENTAL
Intervention: Older African Americans with cognitive impairment
Number of subjects: 135

Group type: COMPARATOR
Intervention: Older Caucasians with cognitive impairment
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Cognitive impairment in African Americans
Number of subjects: 135
Study: 29096790

Group type: EXPERIMENTAL
Intervention: Mean on-treatment BP (systolic and diastolic)
Number of subjects: 5625
Study: 29096803

Group type: EXPERIMENTAL
Intervention: Bioresorbable scaffold (Absorb BVS 1.1) implantation
Number of subjects: 36
Study: 29096996

Group type: EXPERIMENTAL
Intervention: Normal-Tension Glaucoma (NTG) patients
Number of subjects: 13

Group type: COMPARATOR
Intervention: Healthy volunteers (control group)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: NTG patients
Number of subjects: 13

Group type: COMPARATOR
Intervention: NTG patients and healthy volunteers
Number of subjects: 13
Study: 29097234

Group type: EXPERIMENTAL
Intervention: Colorectal resection
Number of subjects: 10
Study: 29097417

Group type: EXPERIMENTAL
Intervention: Patients with HIV in care with viral loads >1500 copies/mL
Number of subjects: 1315

Group type: EXPERIMENTAL
Intervention: Sexually active participants
Number of subjects: 1315

Group type: EXPERIMENTAL
Intervention: Sexually active participants with condomless anal or vaginal sex with an at-risk partner
Number of subjects: 1315

Group type: EXPERIMENTAL
Intervention: Patients with HIV in care with high viral loads and concurrent risk behaviour
Number of subjects: 1315
Study: 29097449

Group type: EXPERIMENTAL
Intervention: CD16-dependent NK cell activation markers
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: FCGR3A-VV genotype frequency
Number of subjects: 103
Study: 29097500

Group type: EXPERIMENTAL
Intervention: Bioclinical model based on clinical and molecular predictors
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Immunohistochemistry staining for CD10, BCL6, MUM1/IRF4, FOXP1, LMO2, BCL2, MYC, P53, and phosphoSTAT3 (pySTAT3) expression
Number of subjects: 91
Study: 29098088

Group type: EXPERIMENTAL
Intervention: Dilute (3%) povidone-iodine solution through a low-pressure pulsatile device
Number of subjects: 50

Group type: COMPARATOR
Intervention: Saline solution through a bulb syringe
Number of subjects: 50
Study: 29098288

Group type: EXPERIMENTAL
Intervention: Hypoglossal nerve stimulator therapy
Number of subjects: 6
Study: 29098299

Group type: EXPERIMENTAL
Intervention: Bioabsorbable steroid-releasing implant (370 µg of mometasone furoate) placed in the frontal sinus ostia (FSO) after endoscopic sinus surgery (ESS)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Bioabsorbable steroid-releasing implant
Number of subjects: 80

Group type: COMPARATOR
Intervention: Surgery alone (control)
Number of subjects: 80
Study: 29098321

Group type: EXPERIMENTAL
Intervention: Sugar-sweetened beverage intake (SSB)
Number of subjects: 34748

Group type: EXPERIMENTAL
Intervention: Suggestive interaction with a genetic variant in the ChREBP-FGF21 pathway (discovery cohorts)
Number of subjects: 34748
Study: 29098467

Group type: EXPERIMENTAL
Intervention: Neurofeedback (NFB)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Methylphenidate (MPH)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Physical Activity (PA)
Number of subjects: 92
Study: 29099620

Group type: EXPERIMENTAL
Intervention: FVC% improvement by ≥MCID
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: FVC% worsening ≥MCID
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: FVC% reliability
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: MCID estimates for FVC% improvement
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: MCID estimates for FVC% worsening
Number of subjects: 300
Study: 29099942

Group type: EXPERIMENTAL
Intervention: High-specific-activity I-131 meta-iodobenzylguanidine (MIBG) therapy at a maximum tolerated dose (MTD) of 296 MBq/kg.
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: High-specific-activity I-131 MIBG therapy
Number of subjects: 21
Study: 29100190

Group type: EXPERIMENTAL
Intervention: Ipilimumab 3 mg/kg every 3 weeks
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Ipilimumab 10 mg/kg every 3 weeks
Number of subjects: 12
Study: 29100192

Group type: EXPERIMENTAL
Intervention: Primary care excision of melanoma
Number of subjects: 9367

Group type: COMPARATOR
Intervention: Secondary care excision of melanoma
Number of subjects: 9367
Study: 29100412

Group type: EXPERIMENTAL
Intervention: Bromocriptine (7.5mg daily) added to spironolactone
Number of subjects: 30
Study: 29101020

Group type: EXPERIMENTAL
Intervention: Quantitative flow ratio (QFR)
Number of subjects: 308
Study: 29101147

Group type: EXPERIMENTAL
Intervention: HAPPY Hearts screening protocol
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Framingham Risk Score
Number of subjects: 1000
Study: 29101272

Group type: EXPERIMENTAL
Intervention: Dystroglycanopathy (DG) cohort
Number of subjects: 52

Group type: COMPARATOR
Intervention: Duchenne-Becker muscular dystrophy (DBMD) cohort
Number of subjects: 52
Study: 29101287

Group type: EXPERIMENTAL
Intervention: European Society of Cardiology 0/1-hour algorithm using hs-cTnT and hs-cTnI in patients with RD
Number of subjects: 487

Group type: EXPERIMENTAL
Intervention: Modifications of the rule-in and rule-out thresholds
Number of subjects: 487

Group type: COMPARATOR
Intervention: Patients with RD
Number of subjects: 487

Group type: COMPARATOR
Intervention: Patients with normal renal function
Number of subjects: 487
Study: 29101463

Group type: EXPERIMENTAL
Intervention: Dovitinib (300 mg in 5 days on/2 days off schedule) with fluvoxamine
Number of subjects: 45

Group type: COMPARATOR
Intervention: Dovitinib (300 mg in 5 days on/2 days off schedule) without fluvoxamine
Number of subjects: 45
Study: 29101542

Group type: EXPERIMENTAL
Intervention: Diet based on REE measured by indirect calorimetry
Number of subjects: 355

Group type: COMPARATOR
Intervention: Diet based on REE estimated by Harris-Benedict equation
Number of subjects: 355
Study: 29101797

Group type: EXPERIMENTAL
Intervention: Amber-tinted blue light-blocking lenses
Number of subjects: 14

Group type: COMPARATOR
Intervention: Clear placebo lenses
Number of subjects: 14
Study: 29101862

Group type: EXPERIMENTAL
Intervention: Initial blood glucose levels
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: HbA1c levels
Number of subjects: 87
Study: 29102040

Group type: EXPERIMENTAL
Intervention: Anti-TPO antibodies
Number of subjects: 1468

Group type: COMPARATOR
Intervention: TSH ≥2.5 mIU/L
Number of subjects: 1468
Study: 29102458

Group type: EXPERIMENTAL
Intervention: Clinical decision support system for nurses to facilitate tobacco smoke exposure screening and counseling
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Clinical decision support system
Number of subjects: 0
Study: 29102579

Group type: EXPERIMENTAL
Intervention: Transcatheter aortic valve replacement (TAVR) with a self-expanding bioprosthesis
Number of subjects: 1030
Study: 29102688

Group type: EXPERIMENTAL
Intervention: Mitral valve repair system (MVRS) via small left thoracotomy
Number of subjects: 30
Study: 29102689

Group type: EXPERIMENTAL
Intervention: Transcatheter mitral valve replacement (TMVR) with a self-expanding, nitinol valve with bovine pericardial leaflets, median deployment time: 14 min (interquartile range: 12 to 17 min).
Number of subjects: 50
Study: 29102811

Group type: EXPERIMENTAL
Intervention: Internal iliac artery ligation (IIAL) for postpartum hemorrhage (PPH)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Healthy postpartum women (control group)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both groups (IIAL and control)
Number of subjects: 0
Study: 29102831

Group type: EXPERIMENTAL
Intervention: Bilateral deficit for rate of force development (RFD) 0-50ms
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Bilateral deficit for rate of force development (RFD) 0-50ms after controlling for physical activity level
Number of subjects: 14
Study: 29103084

Group type: EXPERIMENTAL
Intervention: Reinforced staplers during distal pancreatectomy
Number of subjects: 121
Study: 29103666

Group type: EXPERIMENTAL
Intervention: PI3KR1-rs706716
Number of subjects: 342

Group type: EXPERIMENTAL
Intervention: AKT1-rs3803304, AKT2-rs3730050, PDK1-rs11686903, PI3KR1-rs706716
Number of subjects: 342
Study: 29103916

Group type: EXPERIMENTAL
Intervention: Atorvastatin + Torcetrapib
Number of subjects: 0

Group type: COMPARATOR
Intervention: Atorvastatin + Placebo
Number of subjects: 0
Study: 29104758

Group type: EXPERIMENTAL
Intervention: Revised MSIS-29 scoring structure
Number of subjects: 0

Group type: COMPARATOR
Intervention: Original MSIS-29 scoring structure
Number of subjects: 0
Study: 29105003

Group type: EXPERIMENTAL
Intervention: Asenapine
Number of subjects: 960

Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 960

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 960

Group type: EXPERIMENTAL
Intervention: Anxiety or severe AIA at baseline
Number of subjects: 960

Group type: EXPERIMENTAL
Intervention: Anxiety, irritability, and severe AIA
Number of subjects: 960
Study: 29105491

Group type: EXPERIMENTAL
Intervention: Fear of enacted stigma
Number of subjects: 188

Group type: EXPERIMENTAL
Intervention: Self-devaluation
Number of subjects: 188

Group type: EXPERIMENTAL
Intervention: Weight self-stigma variables
Number of subjects: 188
Study: 29106816

Group type: EXPERIMENTAL
Intervention: Insulin glargine 300 U/mL (Gla-300)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Insulin glargine 100 U/mL (Gla-100)
Number of subjects: 0
Study: 29107010

Group type: EXPERIMENTAL
Intervention: hs-cTnI
Number of subjects: 1142

Group type: EXPERIMENTAL
Intervention: BNP
Number of subjects: 1142

Group type: EXPERIMENTAL
Intervention: Dual-biomarker strategy combining hs-cTnI and BNP with CJb
Number of subjects: 1142
Study: 29107051

Group type: EXPERIMENTAL
Intervention: Florbetaben PET scans
Number of subjects: 205
Study: 29107441

Group type: EXPERIMENTAL
Intervention: Hydroxyurea, median treatment duration 7 years, mean therapeutic dose 18±4.7 mg/kg/day
Number of subjects: 652

Group type: EXPERIMENTAL
Intervention: Hydroxyurea
Number of subjects: 652
Study: 29107621

Group type: EXPERIMENTAL
Intervention: Single-dose azithromycin (30 mg/kg)
Number of subjects: 311
Study: 29108000

Group type: EXPERIMENTAL
Intervention: Missense variants in CD101
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Missense/5' UTR variant in UBE2V1 (among women)
Number of subjects: 100
Study: 29109077

Group type: EXPERIMENTAL
Intervention: Intratumoral injection of mRNA-transfected c-Met-CAR T cells (3 × 10^6 cells)
Number of subjects: 0
Study: 29109298

Group type: EXPERIMENTAL
Intervention: Spinal cord stimulation (SCS)
Number of subjects: 0
Study: 29110152

Group type: EXPERIMENTAL
Intervention: Lapatinib plus trastuzumab (plus endocrine therapy for ER-positive tumors)
Number of subjects: 64
Study: 29110709

Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin/piperaquine (DP)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150
Study: 29110846

Group type: EXPERIMENTAL
Intervention: EGFR mutation testing in aNSCLC patients
Number of subjects: 3382

Group type: EXPERIMENTAL
Intervention: EGFR mutation testing in Caucasian squamous NSCLC patients
Number of subjects: 3382

Group type: EXPERIMENTAL
Intervention: Mutation status concordance between tissue/cytology and plasma samples
Number of subjects: 3382